New Combination Therapy That Increases Progression-Free Survival In Hormone-Receptor-Positive Breast Cancer Patients

Researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center (JCCC) reported an encouraging increase in progression-free survival (PFS, the length of time a patients is on treatment without tumor growth) for patients with breast cancer that was estrogen receptor positive (ER+), HER2-negative who were given a combination of the standard anti-estrogen treatment, letrozole, and a new experimental drug called PD 0332991... via Health News from Medical News Today Read More Here..